Kamari Pharma

Executive Summary

Kamari Pharma is a clinical-stage Israeli biotechnology company pioneering first-in-class TRPV3 inhibitors for rare and severe genetic skin disorders. Its lead program targets TRPV3, a calcium channel implicated in keratinocyte differentiation and itch signaling. By inhibiting TRPV3, Kamari aims to restore skin barrier function and alleviate hyperkeratosis, pain, and chronic itch in conditions such as palmoplantar keratoderma, ichthyosis, and Olmsted syndrome. Founded in 2020, the company has advanced its lead candidate into Phase 1 clinical trials, leveraging a proprietary small-molecule platform that offers potential disease-modifying benefits. Kamari addresses a significant unmet need, as current therapies for these orphan diseases are largely symptomatic and limited in efficacy. Kamari’s approach is supported by strong preclinical data demonstrating target engagement and disease modification in relevant animal models. The company is well-positioned to capitalize on the growing interest in dermatological orphan drugs, with a clear regulatory pathway and potential for accelerated approval given the severity of the conditions. As Kamari progresses through clinical development, successful proof-of-concept in Phase 1 could unlock substantial value and attract partnership interest from larger pharmaceutical companies. The company operates in a niche but high-value segment, with the potential to become a leader in TRPV3-targeted therapies.

Upcoming Catalysts (preview)

• Q2 2027Phase 1 Topline Safety and Efficacy Data40% success
• Q4 2026FDA Orphan Drug Designation for Lead Candidate80% success
• Q3 2027Strategic Partnership or Licensing Deal30% success